From Keith Kerr and colleagues: Personalized cancer medicine

http://www.ncbi.nlm.nih.gov/pubmed/22143935

Virchows Arch. 2012 Jan;460(1):3-8. Epub 2011 Dec 6.
Personalized cancer medicine and the future of pathology.
Moch H, Blank PR, Dietel M, Elmberger G, Kerr KM, Palacios J, Penault-Llorca F, Rossi G, Szucs TD.
Source
Institute of Surgical Pathology, University Hospital Zurich, Schmelzbergstrasse 12, CH-8091, Zurich, Switzerland, holger.moch@usz.ch.

Abstract
In February 2011, a group of pathologists from different departments in Europe met in Zurich, Switzerland, to discuss opportunities and challenges for pathology in the era of personalized medicine. The major topics of the meeting were assessment of the role of pathology in personalized medicine, its future profile among other biomedical disciplines with an interest in personalized medicine as well as the evolution of companion diagnostics. The relevance of novel technologies for genome analysis in clinical practice was discussed. The participants recognize that there should be more initiatives taken by the pathology community in companion diagnostics and in the emerging field of next-generation sequencing and whole genome analysis. The common view of the participants was that the pathology community has to be mobilized for stronger engagement in the future of personalized medicine. Pathologists should be aware of the challenges and the analytical opportunities of the new technologies. Challenges of clinical trial design as well as insurance and reimbursement questions were addressed. The pathology community has the responsibility to lead medical colleagues into embracing this new area of genomic medicine. Without this effort, the discipline of pathology risks losing its key position in molecular tissue diagnostics.